Orasure Technologies Files For Fda Approval Of Oraquick(R) Rapid Hepatitis C Test - When Approved, Expected To Be The First Rapid HCV Test In U.S.

OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that it has submitted a pre-market approval (”PMA”) application to the U.S. Food and Drug Administration (”FDA”) for a rapid test for antibodies to the Hepatitis C virus (”HCV”) utilizing OraSure Technologies’ OraQuick® technology platform. When approved, the OraQuick® HCV test is expected to be the first rapid HCV test approved by the FDA for use in the United States.

More: continued here

Filed under: Liver Disease / Hepatitis on October 29th, 2008